Panuveitis

Summary

Panuveitis (MONDO:0017255) is a disease and 20 clinical trials. Top therapeutic interventions include voclosporin, corticotropin, and sotrastaurin. A subtype of uveitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 20

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	panuveitis
Mondo ID	MONDO:0017255
EFO	EFO:1001082
MeSH	D015864
Orphanet	280898
DOID	DOID:12030
ICD-10-CM	H44.11
ICD-11	1125547814
NCIT	C84989
SNOMED CT	75614007
UMLS	C0030343
MedGen	45303
GARD	0008577
MedDRA	10033687
Is cancer (heuristic)	no

Also known as: diffuse uveitis · panuveitis · panuveitis (disease) · total uveitis

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of uveitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › uveal disorder › uveitis › panuveitis

Related subtypes (8): chorioretinitis, anterior uveitis, intermediate uveitis, iritis, posterior uveitis, suppurative uveitis, idiopathic posterior uveitis, autoimmune uveitis

Subtypes (4): infectious panuveitis, idiopathic panuveitis, Vogt-Koyanagi-Harada disease, sympathetic ophthalmia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Difluprednate	Phase 3 (in late-stage trials)
Voclosporin	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 20.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	9
PHASE4	3
PHASE2	3
Not specified	3
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03656692	PHASE4	TERMINATED	Safety and Effectiveness of Acthar Gel for Inflammation of the Eye’s Uvea (Middle Layer)
NCT05101928	PHASE4	WITHDRAWN	Ozurdex Monotherapy Trial
NCT06085079	PHASE4	UNKNOWN	Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
NCT00167583	PHASE3	COMPLETED	Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet’s Disease (INCYTOB)
NCT00404612	PHASE3	COMPLETED	A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
NCT00404742	PHASE3	COMPLETED	A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
NCT00404885	PHASE3	COMPLETED	A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
NCT00406887	PHASE3	COMPLETED	Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
NCT00407056	PHASE3	COMPLETED	Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis
NCT02595398	PHASE3	COMPLETED	Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
NCT02746991	PHASE3	COMPLETED	Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
NCT03097315	PHASE3	COMPLETED	Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
NCT00615693	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
NCT01280669	PHASE2	WITHDRAWN	Intravitreal Sirolimus as Therapeutic Approach to Uveitis
NCT01789320	PHASE1/PHASE2	COMPLETED	Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
NCT02255032	PHASE2	COMPLETED	Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
NCT00908466	PHASE1	COMPLETED	Sirolimus as Therapeutic Approach to Uveitis
NCT00407316	Not specified	UNKNOWN	Quality of Life and Visual Function in Uveitis Patients
NCT02725177	Not specified	COMPLETED	Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
NCT02952001	Not specified	COMPLETED	MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VOCLOSPORIN	4	3
CORTICOTROPIN	4	1
SOTRASTAURIN	2	3
CHEMBL15720	0	1